Telo Genomics Corp
XTSX:TELO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Genpact Ltd
NYSE:G
|
BM |
Telo Genomics Corp
Total Equity
Telo Genomics Corp
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Telo Genomics Corp
XTSX:TELO
|
Total Equity
-CA$553.3k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Total Equity
CA$82m
|
CAGR 3-Years
62%
|
CAGR 5-Years
157%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Total Equity
$581.3m
|
CAGR 3-Years
13%
|
CAGR 5-Years
7%
|
CAGR 10-Years
40%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Total Equity
$581.8m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
28%
|
CAGR 10-Years
25%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Total Equity
CA$82m
|
CAGR 3-Years
85%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Total Equity
$167.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Telo Genomics Corp
Glance View
Telo Genomics Corp. is a biotech company that is developing the most comprehensive telomere analysis platform in the industry, with powerful diagnostic and prognostic applications. The company is headquartered in Toronto, Ontario. The company went IPO on 2012-02-15. The Company, through its wholly owned subsidiary, Telo Genomics Holdings Corp., is developing diagnostic and prognostic products for numerous diseases that display genomic instability. Its lead application, Telo-MM is being developed to provide information to medical professionals in the treatment of multiple myeloma, a form of blood cancer. The firm's TeloView software consists of two parts, analytical software and a corresponding report designed for clinical decision making. TeloView utilizes the three-dimensional analysis of approximately six parameters generated from the telomeres of a single cell. Its TeloView software generates a report for the clinician that contains information, including the stage of a given disease, its rate of progression and how it responds to therapy. Its solutions include liquid biopsies and related technologies in oncology and neurological diseases.
See Also
What is Telo Genomics Corp's Total Equity?
Total Equity
-553.3k
CAD
Based on the financial report for Dec 31, 2025, Telo Genomics Corp's Total Equity amounts to -553.3k CAD.
